Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis

Minori Miyake-Kashima, Yoji Takano, Mari Tanaka, Yoshiyuki Satake, Tetsuya Kawakita, Murat Dogru, Naoko Asano-Kato, Kazumi Fukagawa, Hiroshi Fujishima

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.

Original languageEnglish
Pages (from-to)587-590
Number of pages4
JournalJapanese Journal of Ophthalmology
Issue number6
Publication statusPublished - 2004 Nov
Externally publishedYes


  • Allergic conjunctivitis
  • Nonsteroidal antiinflammatory drug
  • Objective ocular signs
  • Subjective ocular symptoms

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis'. Together they form a unique fingerprint.

Cite this